Inhibikase Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Inhibikase Therapeutics (IKT).

Price Target Range — 8 Quarters

Analyst Consensus — 8 Analysts

7Buy

1Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$5Upside to Avg. PT+174.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	Chardan Capital	Andreas Argyrides	Initiate	Neutral	$2
Jun 10, 2026	Oppenheimer	—	Initiate	Outperform	$5
Mar 4, 2026	Ladenburg Thalmann	Aydin Huseynov	Initiate	Buy	$4
Jan 21, 2026	B of A Securities	Jason Zemansky	Initiate	Buy	$6
Dec 26, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Assumes	Buy	$8
Dec 17, 2025	Freedom Broker	Ilya Zubkov	Initiate	Buy	$3
Dec 11, 2025	Cantor Fitzgerald	Olivia Brayer	Initiate	Overweight	$4
Mar 28, 2025	HC Wainwright & Co.	Edward White	Maintained	Neutral	—
Feb 12, 2025	HC Wainwright & Co.	Edward White	Downgrade	Buy→Neutral	—
Nov 8, 2024	Jefferies	Dennis Ding	Initiate	Buy	$8
Oct 14, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$15→$5
Aug 16, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$23→$15
May 21, 2024	HC Wainwright & Co.	Edward White	PT Cut	Buy	$27→$23
Mar 7, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$27
Mar 5, 2024	HC Wainwright & Co.	Edward White	Maintained	Buy	$27

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5

Chardan Capital analyst Andreas Argyrides initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Neutral rating and announces Price Target of $1.5.

Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

Oppenheimer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Outperform rating and announces Price Target of $5.

Benzinga Newsdesk

PRO
Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $4.

Benzinga Newsdesk

PRO
B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

B of A Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Overweight rating and announces Price Target of $4.

Benzinga Newsdesk

Inhibikase Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Inhibikase Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5

PRO
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

PRO
Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

PRO
B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

PRO
Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4

People Also Watch

People Also Watch

Inhibikase Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Inhibikase Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROChardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5

PROOppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

PROLadenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

PROB of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

PROHC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

PROCantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4

People Also Watch

People Also Watch

PRO
Chardan Capital Initiates Coverage On Inhibikase Therapeutics with Neutral Rating, Announces Price Target of $1.5

PRO
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

PRO
Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

PRO
B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

PRO
HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

PRO
Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4